Takeda et TiGenix annoncent la publication dans The Lancet des rsultats 24...
TiGenix &8212; Tuesday August 2nd 2016 at 600am UTC ÂÂCOMMUNIQU DE PRESSE Takeda et TiGenix annoncent la publication dans le journal The LancetÂdesÂrsultats 24Âsemaines de l&8217;essai de...
View ArticleKiva introduces CBD Chocolate Bars from 100 California Cannabis Plants
With recent studies indicating that CBD has more healing benefits than THC these products signal a new day for medical marijuana.San Francisco CA PRWEB August 02 2016 Kiva just announced its new...
View ArticleEndoscopy for Detecting Adenocarcinoma in Crohn's Disease
Endoscopy lacks sensitivity for detecting small bowel adenocarcinoma SBA in patients with Crohn's disease researchers from France and the Netherlands report. Reuters Health Information
View ArticleStoma CareOstomy Care and Accessories Market by Procedure Bags Accessories &...
LONDON Aug. 2 2016 PRNewswire The global ostomy care market is expected to reach USD 3.41 billion by 2021 from USD 2.62 billion in 2016 at a CAGR of 5.4 from 2016 to 2021. Based on type of procedure...
View ArticleTakedaTigenix stem cell therapy hits targets in Crohns trial
Takeda and TiGenix' stem cell therapy has shown promise in inducing remission of perianal fistulas in patients with Crohn's disease according findings of a latestage trial published in The Lancet.
View ArticleUPDATED TiGenix finishes Phase III Stem Cell therapy to treat Crohns disease
Belgium is a real pioneer in developing stem cell therapies. TiGenix pushes this precursor position even further by presenting good results from a Phase III of its stem cell therapy Cx611 treating...
View ArticleTakeda and TiGenix Announce Publication in The Lancet of 24Week Results of...
Osaka Japan August 2 2016 and Leuven Belgium August 2 2016 – Takeda Pharmaceutical Company Limited TSE 4502 “Takeda” and TiGenix NV Euronext Brussels TIG...
View ArticleTakeda and TiGenix publish 24week results of Cx601 trial in Crohn's
Japanese pharma company Takeda and Belgian biopharmaceutical company TiGenix have announced the publication
View ArticleNektar Therapeutics Reports Financial Results for the Second Quarter of 2016
SAN FRANCISCO Aug. 3 2016 PRNewswire Nektar Therapeutics Nasdaq NKTR today reported its financial results for the second quarter ended June 30 2016. Cash and investments in marketable securities at...
View ArticleAmerican Gastroenterological Association Establishes NIHFunded Registry to...
BETHESDA Md. Aug. 4 2016 PRNewswireUSNewswire &160;Today the American Gastroenterological Association AGA announced that it has received funding from the National Institute of Allergy and...
View ArticledoTERRA Wellness Advocate Starts a Community Support Group for People with...
PLEASANT GROVE Utah Aug. 4 2016 PRNewswire &160;After suffering from chronic pain and depression for several years doTERRA Wellness Advocate Tracy Strand reached out to find a support group within...
View ArticleGut levels of IL9 Th9 may be markers in patients with PsA
A recently published study showed interleukin9 and T helper 9 cells identified in the gut microbiome of patients with psoriatic arthritis and may play a role in in the disease.Researchers enrolled 25...
View ArticleDutch FF Pharma has a Promising Immunotherapy to fight Crohns Disease
Arrivederci Italia We&8217;re going to fly up to the Netherlands for another Biotechrelated adventure This time we&8217;re visiting Utrecht the fourth most populated city in the country and...
View ArticleNew Study Suggests Link Between Mesothelioma and Crohns Disease According to...
New research out of Duke University has scientists looking more closely at a possible connection between peritoneal mesothelioma and inflammatory bowel disease.Raleigh NC PRWEB August 07 2016...
View ArticleFe3 Medical an InCube Labs Company Receives $3.5M Investment from the State...
SAN ANTONIO Aug. 8 2016 PRNewswire &160;Fe3 Medical an InCube Labs company today announced that the State of Texas has invested $3.5M as part of an extension to the company's Series B...
View ArticlePhase 3 results for Cx601 in treatment of complex perianal fistulas in...
Takeda Pharmaceutical Company Limited and TiGenix NV have announced that the 24week results of the Phase 3 ADMIRECD trial investigating Cx601 have been published in The Lancet . Cx601 is a suspension...
View ArticleArena Pharmaceuticals Reports Second Quarter 2016 Financial Results and...
SAN DIEGO Aug. 8 2016 PRNewswire Arena Pharmaceuticals Inc. Nasdaq ARNA today reported financial results for the second quarter ended June 30 2016 and provided a corporate update."We are continuing to...
View ArticleInstavit is an Official Contributor to British House in Rio
LONDON Aug. 9 2016 PRNewswire Instavit the doctor formulated smart supplement solution is an official contributor to British House the U.K.'s home away from home. From August 5 through 21 British House...
View ArticleCelgeneAktie wichtige Morbus CrohnStudiendaten stehen an Aktienanalyse
New York CelgeneAktienanalyse von Analyst Brian Abrahams von Jefferies & Co Aktienanalyst Brian Abrahams vom Investmenthaus Jefferies & Co bekrftigt laut einer Aktienanalyse seine Kaufempfehlu...
View ArticleContraceptive Use and Risk of Crohn's Disease Complications
Which types of contraceptives increase risk of surgery in women with Crohn disease Gastroenterology
View Article